DOCSLIB.ORG

GEIS 2019 Bench to Bedside SHORTER

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GEIS 2019 Bench to Bedside SHORTER ! ➙ " or " ➙ ! Which is a better fit in sarcoma research? Robert Maki, MD PhD Financial COI Bayer Deciphera Karyopharm Lilly / Imclone Pfizer Springworks UptoDate American Society for Clinical Oncology American Association for Cancer Research • Examples of bench ➙ bedside Outline • Muramyl tripeptide in osteosarcoma • PARP inhibitors in Ewing sarcoma (…CDK12, LSD1) • IGF1R in rhabdomyosarcoma, Ewing sarcoma • … • Examples of bedside ➙ bench • Trabectedin in myxoid-round cell liposarcoma • Defining Ewing-like sarcomas • TKI in desmoid tumor, soft tissue sarcomas • Germ line alterations in sarcoma patients (cancer patients in general) • … • Examples of convergence • Immunotherapy in sarcomas, NY-ESO-1, immune checkpoint inhibitors. • GIST • MYC amplification and chemotherapy sensitivity • Which works “better”? • In which direction will the arrow point 2020-2025? !➙ " Medical oncology: “all” bedside to bench (bootstrapping = arrancar[se]?) Goodman LS et al. JAMA 1946; 132: 126 Muramyl tripeptide (MTP): Eugenie Kleinerman Meyers PA and Chou AJ. Current Advances in Osteosarcoma. Adv Exp Med Biol., Vol 804, 2014 MTP (mifamurtide) • Synthetic derivative of BCG cell wall peptidoglycan • Serves as an adjuvant for immune responses • Encapsulating in liposomes increased macrophage uptake • Spontaneous metastases in mice eliminated with IV MDP • MTP makes human monocytes tumoricidal • Imaging of radioactive MTP: taken up in spleen, liver, lungs, nasopharynx, and occasionally tumor • Phase I: MTD 6 mg/m2: Fever, chills, malaise, nausea • Optimal biological dose defined as 0.5 – 2 mg/m2 Zwilling BS, Campolito LB. J Immunol 1977; 119: 838. PMID 330756 FiDlEr IJ et al. PNAS 1981; 78: 1680. PMID 6940181 KlEinErman ES Et al. CancEr REs 1983; 43: 2010. PMID 6831430 Murray JL Et al. JCO 1989; 7: 1915. PMID 2479721 MTP (mifamurtide) • Dog osteosarcoma model: MTP vs placebo post amputation • Median overall survival 77 d (placebo) vs 222 d (MTP) MacEwen EG et al. JNCI 1989; 81: 935. PMID 2733037 Summary data: Osteosarcoma Rx Neo/adjuvant chemo ± Ifosfamide, ± MTP Ifosfamide made no difference Mifamurtide made a difference Meyers PA et al. JCO 2008; 26: 633 ! ➙ " Trabectedin in myxoid-round cell liposarcoma (MRCLS) • Compassionate use study showed better results in in MRCLS than other sarcoma subtypes • n=51 • 2 CR, 24 PR = RR 51% • Tumor density changes seen before shrinking in patients • (Choi response in GIST) • Median PFS 14 months, 88% 6-month PFS • Differentiation induced in some tumors • Some data on mechanism of action only years later (D’Incalci) • FUS-DDIT3 translocation product dropped off promoters Grosso F et al. Lancet Oncol 2007; 8: 595 PMID 17586092 Forni C et al. Mol Cancer Ther 2009; 8: 449 PMID 19190116 Di Giandomenico S et al. Oncogene 2014; 33: 5201 PMID: 24213580 Defining Ewing-like sarcomas • Some ”translocation-negative” Ewing sarcomas did not respond well to chemotherapy • One pediatric sarcoma was seen to have CIC-DUX4 in 2009 • Identification of EWSR1-negative Ewing-like sarcomas • CIC-DUX4 < EWSR1-FLI1 outcomes • BCOR-CCNB3 > EWSR1-FLI1 outcomes • Knowledge of the fusions provides a tool for better understanding biology Yoshimoto M et al. Cancer Genet Cytogenet 2009; 195: 1 PMID 19837261 Graham C et al. Hum Pathol 2012; 43: 180 PMID 21813156 Italiano A et al. GCC 2012; 51: 207 PMID 22072439 Pierron G et al. Nat Genet 2012; 44: 461 PMID 22387997 Choi EY et al. Am J Surg Pathol 2013; 37: 1379 PMID 23887164 Puls F et al. Am J Surg Pathol 2014; 38: 1307 PMID 24805859 ! ⇆ " NY-ESO-1 in sarcoma subtypes • Hunt for genuinely tumor-specific antigens • Found in esophageal squamous cell cancer patient serological screen • NY-ESO-1 = Cancer-germ line antigen (testis, ovary) • Synovial sarcoma 1st sarcoma found with NY-ESO-1 • Later shown expressed in myxoid-round cell liposarcoma • Led to studies of NY-ESO-1 engineered T cells / CAR - T Chen YT et al. Cytogenet Cell Genet 1997; 79: 237 PMID 9605863 Jungbluth AA et al. Int J CanCer 2001; 94: 252 PMID 11668506 Segal NH et al. Cancer Immun 2005; 5: 2 PMID 15683221 PollaCk SM et al. CanCer 2012; 118: 4564 PMID: 22359263 Robbins PF et al JCO 2011; 29: 917 PMID: 21282551 D’Angelo SP et al CanCer DisCov 2018; 8: 944 PMID: 29891538 Immune checkpoint inhibitors in UPS, ASPS, angiosarcoma • SARC 28: pembrolizumab phase II • n=70, 1/10 CR, 3/10 PR on pembrolizumab, rare other PR • Alliance: nivolumab ± ipilimumab • n=86, CR in Myxofibro, ULMS; PR in UPS, LMS, angio, ASPS • GSF: Cyclophosphamide + pembrolizumab phase II • n=50 evaluable, only 1 PR (UPS) • Combination trials • PD1 and PDL1 mAb combination phase I studies • Axitinib and pembrolizumab with (mostly) ASPS responses • Why? High PD-L1 (< 5% of tumors?), TMB (only moderate) Tawbi HA et al. Lancet Oncol 2017; 18:1493 PMID 28988646 D’Angelo SP et al. Lancet Oncol. 2018; 19:416 PMID: 29370992 Toulmonde M et al. JAMA Oncol. 2018; 4:93 PMID: 28662235 Wilky BA et al. Lancet Oncol 2019, 20: 837 PMID 31078463 ”Leiomyosarcoma of the GI tract”, n=54 Diagnosed before 1975, minimum 10 years’ follow-up Evans HL. Cancer 1985; 56: 2242. PMID 4052969 W/W GIST diagnosis and treatment W/Wv • GI leiomyosarcomas (pre 1998): do not respond to chemotherapy like other leiomyosarcomas • Peritoneal, liver metastases seen • Studies of KIT in W/W mice ICC • ”W/W”: lack extracellular domain in KIT (dominant spotting) • Mast cell, melanocyte, neuronal expression altered, anemia • W/Wv “black eye/white” mice have bowel motility problems, no ICCs, other developmental problems • 1994: Mutation in KIT in mast cell leukemia GIST • 1998: Mutation in KIT in GIST • 1998: Detection of KIT mutation in familial GIST del559 Hirota S et al. Science 1998; 279: 577 PMID 9438854 Nishida T et al. Nat Genet 1998; 19: 323 PMID 9697690 Well, which works “better”? • Both are compelling ! • Moving a basic science finding to the clinic and showing its effectiveness • Many well-conceived lines of research end up with no clinically useful result • “MELK inhibitor” OTS964 is actually a CDK11B inhibitor • However, clinical observation can be useful too, cueing research in the laboratory – serendipity • In many instances, there are elements of both methodicality and observation • For the omniscient, you do not need either approach • For the rest of us, both avenues together provide the greatest chance of success for an individual patient or a group of patients as a whole Lin A et al. Sci Trans Med 2019; 11: eaaw8412 Where are we going in the next 5 years? • Greater attention to specific histologies or molecular abnormalities within histologies • New Rx / biology to pursue: • Epigenetics • Metabolism • Poisoning dependencies – lactate in ASPS, glutamine in KEAP1 mutated tumors, more on TOR? • Oxidative stress • Further exploration of kinase inhibitors (> 400 human kinase identified) • Protein acetylation, ubiquitination, and other modifications • Immunology • CAR-T for specific diagnoses – more than synovial sarcoma and M/RC liposarcoma? • Vaccine + checkpoint inhibitor • Checkpoint inhibitor + other immunostimulant • Regulation of the RNA world • Antisense Rx of miRNA, piRNA, lncRNA, MYC or other difficult to target oncogenes? • Clinical trials should aim for big / meaningful signals • For diagnoses without new agents (osteo, Ewing sarcoma) - do better with what we have • Shorter course Rx for Ewing sarcoma vs standard, e.g. - End - CONDUCCIÓN AGRESIVA ESTRICTAMENTE APLICADA In New York, aggressiveness is not just a suggestion, IT’S THE LAW! Bob Maki MD @ gmail . com.
Load more

Recommended publications
  • 2018 Annual Meeting Trevi Fountain (Fontana Di Trevi), Rome November 14 - 17, 2018 Rome Cavalieri Hotel • Rome, Italy
    Connective Tissue Oncology Society 2018 Annual Meeting Trevi Fountain (Fontana di Trevi), Rome November 14 - 17, 2018 Rome Cavalieri Hotel • Rome, Italy Wednesday, 14 November, 2018 12:00 pm - 6:00 pm Registration Salon de Cavalieri 1 & Gallery 6:00 pm - 8:00 pm Welcome Reception San Pietro Gallery Thursday, 15 November, 2018 6:00 am - 7:00 am Registration Salon de Cavalieri 1 & Gallery 7:00 am - 8:00 am Coffee and Posters Salon de Cavalieri 1 & Gallery 8:00 am - 5:30 pm 4th International Sarcoma Nurse and Allied Caravaggio Room Professionals Meeting (iSNAP) - "Collaboration in Sarcoma Care - Realizing Better Outcomes" 9:00 am - 11:00 am – SARC PROGRAM – Salon del Cavalieri 2,3,4 Chawla/Rosenfeld Developmental Therapeutics Symposium Emerging and Novel Biologically Targeted Approaches for Sarcoma Patients Introduction Elizabeth Lawlor, MD, PhD Robert Maki, MD, PhD Enhancing Activity of B7-H3 CAR T Cells for Pediatric Sarcomas Robbie Majzner, MD Discussion / Q & A Translating PARP Inhibition as a TherapeuticSARC Target @ into CTOS Benefit for Patients with Sarcoma November 15, 2018 Sandra Strauss, MD, PhD 9:00 AM - 11:00 AM Rome Cavalieri Hotel Discussion / Q & A Rome, Italy Epigenetic Changes following the Loss of PRC2 in MPNST: Emerging Therapeutic Opportunities Keila Torres, MD, PhD Chawla/Rosenfeld Developmental Therapeutics Symposium Discussion / Q & A 2019 Career DevelopmentEmerging and Update novel biologically targeted approaches for sarcoma patients Elizabeth Lawlor, MD, PhD 9:00 AM Elizabeth Lawlor, MD, PhD Introduction Robert
    [Show full text]
  • We Will Find a Cure Together 2016 Annual Report Table of Contents
    WE WILL FIND A CURE TOGETHER 2016 ANNUAL REPORT TABLE OF CONTENTS LETTER FROM THE CO-FOUNDERS 3 WHAT WE DO AND WHY IT MATTERS 5 DTRF-FUNDED RESEARCH 6 FINANCIALS 7 THIRD INTERNATIONAL DTRF DESMOID TUMOR RESEARCH WORKSHOP 9 OUR COMMUNITY 10 ANNUAL SIGNATURE DTRF EVENTS 11 DTRF ANNUAL PATIENT MEETING 12 OUR TEAM 13 A LETTER FROM THE CO-FOUNDERS Dear Friends, Thank you for your interest in our Annual Report as we press forward to find new treatments for desmoid tumors! 2016 has been a year of exciting developments: PRO Tool. We continue our work in developing the first validated Patient Reported Outcome (PRO) tool in desmoid tumors with Dr. Mrinal Gounder of Memorial Sloan Kettering Cancer Center and Quintiles. We have had great success in recruiting patients to aid in this process. This tool, which will provide the framework for collecting data on the patient’s experience with a particular treatment, is intended to facilitate a new regulatory endpoint that can be used in all future clinical trials. It will be a great advancement in the field for researchers worldwide and is intended to facilitate future FDA approval of treatments for desmoid tumors. We anticipate that the PRO will be trial-ready in early 2017. DTRF Desmoid Tumor Patient Registry. We’re also nearing the Jeanne Whiting, President/Co-founder and Marlene finish line of accomplishing our goal of establishing a desmoid Portnoy, Executive Director/Co-founder tumor patient registry. DTRF was fortunate to be one of twenty rare disease organizations selected for a natural history study project initiated by the National Organization of Rare Disorders (NORD), in partnership with the FDA.
    [Show full text]
  • Patientderived Xenografts for Individualized Care in Advanced Sarcoma
    Original Article Patient-Derived Xenografts for Individualized Care in Advanced Sarcoma Justin Stebbing, MA, FRCP, FRCPath, PhD1; Keren Paz, PhD2; Gary K. Schwartz, MD3; Leonard H. Wexler, MD3; Robert Maki, MD, PhD4; Raphael E. Pollock, MD, PhD5; Ronnie Morris, MD2; Richard Cohen, MD6; Arjun Shankar, MD6; Glen Blackman, MBBS7; Victoria Harding, MD1; David Vasquez, MD2; Jonathan Krell, MD, PhD1; Daniel Ciznadija, PhD2; Amanda Katz, MD2; and David Sidransky, MD8 BACKGROUND: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of- care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in con- ducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method (“TumorGrafts”). METHODS: Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment. RESULTS: Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients. Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft-predicted therapy. CONCLUSIONS: The current data support the use of the personalized TumorGraft model as an investigational platform for therapeu- tic decision-making that can guide treatment for rare tumors such as sarcomas.
    [Show full text]
  • Sarcoma Journal an Exciting Initiative in Peer-Reviewed Professional Education and Advocacy PAGE 4
    VOL 1 | NO 1 | FALL 2017 WWW.SARCOMAJOURNAL.COM theSARCOMA Official Journal of The Sarcoma Foundation JOURNAL of America™ FEATURE ARTICLE Sof t Tissue Sarcoma: Diagnosis and treatment PAGE 7 EDITORIAL Introducing The Sarcoma Journal An exciting initiative in peer-reviewed professional education and advocacy PAGE 4 CASE REPORT Bilateral chylothorax in an AIDS patient with newly diagnosed Kaposi sarcoma PAGE 20 CASE REPORT Pulmonary sarcomatoid carcinoma presenting Premier Issue as a necrotizing cavitary lung lesion Diagnostic dilemma PAGE 22 › EDITORIAL‹ VIEWS AND NEWS BY WILLIAM D. TAP, MD | Editor-In-Chief Introducing The Sarcoma Journal—The Official Journal of the Sarcoma Foundation of America™: An Exciting Initiative in Peer-Reviewed Professional Education and Patient Advocacy › I WELCOME YOUR he Sarcoma Journal — Official ing affiliations with the Sarcoma Foun- PARTICIPATION IN Journal of the Sarcoma Founda- dation of America and its comprehensive THE SUCCESS OF THE tion of America™ represents a program of sarcoma research, patient sup- SARCOMA JOURNAL Tnew and exciting initiative in pro- port and education and advocacy. As you fessional education. We invite you to share explore the first issue of the journal, you BY SUBMITTING in the excitement surrounding the launch will discover how our editorial content is MANUSCRIPTS, of a medical journal designed to be your an extension of this three-tiered approach. INTERESTING CASE most authoritative and comprehensive The SFA program is characterized by a STUDIES, ORIGINAL source of scientific information on the di- multi-dimensional and uniquely coordi- RESEARCH, AND TOPIC agnosis and treatment of sarcomas and sar- nated outreach program of videos and we- PERSPECTIVES—AS coma sub-types.
    [Show full text]
  • Sarcoma European & Latin American Network (Selnet
    Sarcomas SARCOMA EUROPEAN & LATIN AMERICAN NETWORK (SELNET) RECOMMENDATIONS ON PRIORITIZATION IN SARCOMA CARE DURING COVID-19 PANDEMIC a,b a,b c d JAVIER MARTIN-BROTO,MDPHD , NADIA HINDI, MD, SAMUEL AGUIAR JR MD, RONALD BADILLA-GONZÁLEZ, MD, e f g h,i,j VICTOR CASTRO-OLIDEN, MD, MATIAS CHACÓN, MD, RAQUEL CORREA-GENEROSO, MD, ENRIQUE DE ALAVA,MDPHD, k l m n DAVIDE MARÍA DONATI, MD, MIKAEL ERIKSSON, MD, MARTIN FALLA-JIMENEZ, MD, GISELA GERMAN, MD, o p q e MARIA LETICIA GOBO SILVA, MD, FRANCOIS GOUIN, MD, ALESSANDRO GRONCHI, MD, JUAN CARLOS HARO-VARAS, MD, r s t u NATALIA JIMÉNEZ-BRENES, MD, BERND KASPER, MD, CELSO ABDON LOPES DE MELLO, MD, ROBERT MAKI,MDPHD, a v w x PAULA MARTÍNEZ-DELGADO,PHD, HECTOR MARTÍNEZ-SAID, MD, JORGE LUIS MARTINEZ-TLAHUEL, MD, JOSE MANUEL MORALES-PÉREZ, MD, y z aa FRANCISCO CRISTOBAL MUÑOZ-CASARES, MD, SUELY A. NAKAGAWA, MD, EDUARDO JOSE ORTIZ-CRUZ,MDPHD, bb cc a dd EMANUELA PALMERINI,MDPHD, SHREYASKUMAR PATEL, MD, DAVID S. MOURA,PHD, SILVIA STACCHIOTTI, MD, ee ff f gg MARIE PIERRE SUNYACH, MD, CLAUDIA M. VALVERDE, MD, FEDERICO WAISBERG, MD, JEAN-YVES BLAY,MDPHD aGroup of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain; bDepartment of medical oncology, University Hospital Virgen del Rocio, Seville, Spain; cDepartment of Pelvic Surgery, A.C. Camargo Cancer Center, S~ao Paulo, Brazil; dDepartment of medical oncology, Rafael Angel Calderón Guardia Hospital, San José, Costa Rica; eDepartment of medical oncology, Instituto Nacional
    [Show full text]
  • Second International DTRF Desmoid Tumor Research Workshop October 18, 2015 Participant Profiles
    Second International DTRF Desmoid Tumor Research Workshop October 18, 2015 Participant Profiles updated on 10.27.15 Mushriq Al-Jazrawe, University of Toronto, Laboratory Medicine & Pathobiology Mushriq received his bachelor of science at the University of Toronto in Genes, Genetics, and Biotechnology. He is currently a PhD candidate in the Department of Laboratory Medicine & Pathobiology, University of Toronto in Dr. Benjamin Alman lab, studying the role of platelet- derived growth factor signaling and microRNAs in desmoid tumors. Benjamin Alman, MD, Department Chair, Orthopedic Surgery, Duke University Dr. Alman is an orthopaedic clinician-scientist, whose research focuses on understanding role of developmentally important processes in pathologic and reparative process involving the musculoskeletal system. The long-term goal of his work is to use this knowledge to identify improved therapeutic approaches to orthopaedic disorders. He makes extensive use of genetically modified mice to model human disease, and has used this approach to identify new drug therapies for musculoskeletal tumors and to improve the repair process in cartilage, skin, and bone. He also works on cellular heterogeneity in sarcomas, and has identified a subpopulation of tumor initiating cells in musculoskeletal tumors. In this work, he also has identified specific cell populations that are responsible for joint and bone development. He has was recently recruited from the University of Toronto to Duke University to chair the department of orthopaedics, which was established in 2010, and includes a large musculoskeletal research component. He has half his time protected for his research work. Dr. Alman is the Principal Investigator in the DTRF-funded collaborative project, "Collaboration for a Cure: Identifying new therapeutic targets for desmoid tumors." Profile here.
    [Show full text]
  • Clinical Recommendations Margins)
    Annals of Oncology 20 (Supplement 4): iv132–iv136, 2009 clinical recommendations doi:10.1093/annonc/mdp153 Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up P. G. Casali1, L. Jost2, S. Sleijfer3, J. Verweij3 & J.-Y. Blay4 On behalf of the ESMO Guidelines Working Group* 1Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy; 2Department of Oncology, Kantonsspital, Bruderholz, Switzerland; 3Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands; 4INSERM U590, Claude Bernard University and Department of Oncology, Edouard Herriot Hospital, Lyon, France The following recommendations apply to adult-type soft tissue performed by a trained surgeon, or discussed between the sarcomas arising from limbs and superficial trunk. surgeon and the radiologist. It should be planned in such a way Recommendations on retroperitoneal sarcomas, desmoid-type that the biopsy pathway and the scar can be safely removed on fibromatosis and uterine sarcomas are provided separately at definitive surgery, and should be preceded by imaging the end of the chapter with regard to those main aspects by [contrast-enhanced magnetic resonance imaging (MRI) is the which they differ from more frequent soft tissue sarcomas. In preferred method for limb and superficial trunk lesions]. general, the main principles of diagnosis and treatment may Histological diagnosis should be made according to the well apply to all soft tissue sarcomas, including the rarest World Health Organization (WHO) classification. The presentations [e.g. visceral sarcomas other than gastrointestinal malignancy grade should be provided in all cases in which this stromal tumors (GIST), head and neck sarcomas], which is feasible based on available systems.
    [Show full text]
  • Speaker Bios
    Second International Chordoma Research Workshop April 3–5, 2008 Speaker Biographies Christopher Austin, M.D. Dr. Christopher Austin is Director of the NIH Chemical Genomics Center (NCGC) and Senior Advisor to the Director for Translational Research at the National Human Genome Research Institute (NHGRI). NCGC, part of the NIH Roadmap Molecular Libraries initiative, develops small‐molecule probes for biological functions and new paradigms for high‐throughput screening, chemistry, and cheminformatics. In his role as Senior Advisor for Translational Research, he initiated the Knockout Mouse Project, which is producing knockout mice for all mouse genes, and an in‐depth transcriptome map of the mouse. Dr. Austin came to NIH from Merck and Co., where he directed research programs in genomics‐based target discovery, pharmacogenomics, and DNA microarray technologies, with a focus on neuropsychiatric diseases. Dr. Austin received his A.B. from Princeton University and M.D. from Harvard University. He did clinical training in neurology at Massachusetts General Hospital, followed by a fellowship in genetics at Harvard. Laurence Baker, D.O. Dr. Laurence Baker is Professor of Internal Medicine and Pharmacology in the Departments of Internal Medicine and Pharmacology, Division of Hematology/Oncology, University of Michigan Medical School. He received his medical degree from the University of Osteopathic Medicine and Surgery in Des Moines, Iowa, in 1966. He did a medical residency at Detroit Osteopathic Hospital, which was followed by an oncology fellowship at Wayne State University. He joined the faculty of the Department of Oncology at Wayne State upon completion of his fellowship in 1972. In 1987, Dr. Baker became the Director of the Meyer L.
    [Show full text]
  • SPRING 2011 Accelerating Science, Advancing Medicine
    Dean’s Quarterly SPRING 2011 ACCELERATING SCIENCE, ADVANCING MEDICINE Becoming an Engine of Discovery I am pleased to outline the strategic plan for the Center for Discovery and Innovation (CDI) at The Mount Sinai Medical Center. This entity, designed to capitalize on the unprecedented opportunities of 21st century biomedicine, will bring together some 30 renowned translational scientists, many of whom are successful drug developers and patent-holders already, with the charge of translating discovery into therapeutics and generating new intellectual property. Under the direction of a senior leader with Experimental Therapeutics Institute in five key international stature in translational medicine areas: small-molecule drug discovery, monoclonal and the successful development of therapeutic antibodies and purified proteins, high-content interventions, the CDI discovery group will screening/RNAi, induced pluripotent stem cells, identify the most promising research within all of and systems pharmacology and network analysis Mount Sinai’s disease-focused institutes with the facilities. goal of illuminating new disease targets and the The success of the CDI enterprise and the Dennis S. Charney, MD, is the Anne and Joel Ehrenkranz molecules that treat those targets. scientists it recruits and supports will ultimately Dean of Mount Sinai School of Medicine and the Executive Vice President for Academic Affairs of The Mount Sinai This new era of growth will span years and will be measured by the discoveries made, and the Medical Center. require great institutional commitment and applications developed, to predict, prevent, investment, and the results will be breathtaking. and treat disease. I look forward to sharing with The CDI is structured to focus on five areas that you the progress and results of CDI throughout To learn more, visit www.mountsinai.org/Charney represent the most pressing global disease burden: the coming years.
    [Show full text]
  • The People & Partnerships of the Tisch
    THE PEOPLE & PARTNERSHIPS OF THE TISCH CANCER INSTITUTE 2012 Report INTRODUCTION 1 STUArt AAronson + PREMKUMAR REDDY 3 Eric SCHAdt + AndrEW KASARKIS 5 GEorgE RAPTIS + ELISA Port 6 SErgio LIRA + MIRIAM MERAD 6 CARLOS Cordon-CArdo 10 RonALD HOFFMAN + IHOR LEMISCHKA 10 RAndALL HOLcoMBE + DANIEL LABOW 12 ROBErt MAKI + JAMES WITTIG 14 WILLIAM OH 15 Scott FRIEDMAN + JosEP LLOVET 16 MARSHALL POSNER + ERIC GENDEN 17 RAJA FLORES 21 PAOLO BoFFETTA + WILLIAM REDD 21 LUIS ISOLA 22 SUNDAR JAGANNATH 22 KENNETH RosENZWEIG 24 PHILip FRIEDLANDER + YVONNE SAENGER 24 OUR FUTURE 27 THE TiscH CANCER InstitUTE SEnior LEADErsHIP 28 DEAR FriEnds & coLLEAguES, I joined Mount Sinai in December 2007 to establish a cancer institute that would expand upon Mount Sinai’s strengths as a world-class institution. In 2008, a generous gift from Trustee James S. Tisch and his wife, Merryl H. Tisch, created a significant endowment, enabling the naming of the Institute and demonstrating considerable confidence in the Institute’s potential. Now, I am pleased to share this report on our progress. Cancer research and care at Mount Sinai reflects a collaborative, multidisciplinary approach. “Bench-to- bedside” translation is possible because of the strong relationship between Mount Sinai School of Medicine and the Mount Sinai Hospital. Our investigators have the opportunity to work directly with a large and diverse patient Steven J. Burakoff, MD, Director of population, creating exceptional conditions for translational The Tisch Cancer Institute research that is grounded in outstanding clinical care. During my tenure as Director of The Tisch Cancer Institute, we’ve recruited more than 30 acclaimed physicians and researchers, specializing in basic research, clinical research, and population science.
    [Show full text]
  • Soft-Tissue Sarcomas Published on Cancer Network (
    Soft-Tissue Sarcomas Published on Cancer Network (http://www.cancernetwork.com) Soft-Tissue Sarcomas June 01, 2016 | Cancer Management [1] By Peter W. T. Pisters, MD [2], Mitchell Weiss, MD [3], Robert Maki, MD, PhD [4], and Chandrajit P. Raut, MD, MSc [5] The soft-tissue sarcomas are a group of rare but anatomically and histologically diverse neoplasms. This is due to the ubiquitous location of the soft tissues and the nearly three dozen recognized histologic subtypes of soft-tissue sarcomas. Overview The soft-tissue sarcomas are a group of rare but anatomically and histologically diverse neoplasms. This is due to the ubiquitous location of the soft tissues and the nearly three dozen recognized histologic subtypes of soft-tissue sarcomas. It is estimated that in 2016 approximately 12,310 new cases of soft-tissue sarcoma will be identified in the United States, and 4,990 patients will die of the disease. The age-adjusted incidence is 3.3 cases per 100,000 persons. Epidemiology Sarcomas constitute less than 1% of all cancers, but 15% of cancers in children, although bone tumors predominate in children. There are familial syndromes in which sarcomas are common, but such genetic conditions are rare. Gender There is a slight male predominance, with a male-to-female ratio of 1.1:1. Some sarcomas, such as desmoplastic small round cell tumor, demonstrate a distinct male predominance. Age The age distribution in adult soft-tissue sarcoma studies is as follows: 20.7% of patients are < 40 years of age; 27.6% are 40 to 60 years old; and 51.7% of patients are > 60 years.
    [Show full text]
  • Patientderived Xenografts for Individualized Care in Advanced Sarcoma
    Original Article Patient-Derived Xenografts for Individualized Care in Advanced Sarcoma Justin Stebbing, MA, FRCP, FRCPath, PhD1; Keren Paz, PhD2; Gary K. Schwartz, MD3; Leonard H. Wexler, MD3; Robert Maki, MD, PhD4; Raphael E. Pollock, MD, PhD5; Ronnie Morris, MD2; Richard Cohen, MD6; Arjun Shankar, MD6; Glen Blackman, MBBS7; Victoria Harding, MD1; David Vasquez, MD2; Jonathan Krell, MD, PhD1; Daniel Ciznadija, PhD2; Amanda Katz, MD2; and David Sidransky, MD8 BACKGROUND: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of- care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in con- ducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method (“TumorGrafts”). METHODS: Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment. RESULTS: Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients. Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft-predicted therapy. CONCLUSIONS: The current data support the use of the personalized TumorGraft model as an investigational platform for therapeu- tic decision-making that can guide treatment for rare tumors such as sarcomas.
    [Show full text]